About Rezolute
Rezolute is a publicly listed company based in Denver (United States) founded in 2012 by Nevan Charles Elam and Hoyoung Huh. Therapies for metabolic and orphan diseases are developed by Rezolute. The company has 59 employees. Its chief executive, as recorded, is Nevan Charles Elam. Its website rezolutebio.com draws about 11 thousand monthly visits. Rezolute offers products and services including Ersodetug. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is Rezolute, Inc. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI), has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) hereditary angioedema (HAE). In Dec 2017, the company had entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.
- Headquarters Denver, United States
- Employees 59
- Founders Nevan Charles Elam, Hoyoung Huh
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rezolutebio.com
- Social LinkedIn X Facebook
- Legal Name Rezolute, Inc.
- Net Profit-$77.59 M (USD)-4.27as on Jun 30, 2026
- EBITDA-$82.94 M (USD)-3.85as on Jun 30, 2026
- Latest Funding Round$41M (USD), Post-IPO
Oct 2020
- InvestorsCitadel
& 6 more
- Employee Count59
Products & Services of Rezolute
Rezolute offers a comprehensive portfolio of products and services, including Ersodetug.
Drug for treating congenital hyperinsulinism in clinical trials
Funding Insights of Rezolute
- Total Rounds 25
- Last Round Post-IPO — $41M
- First Round $1.83M
(Aug 2012)
- Investors Count 7
Latest 10 of 25 funding rounds of Rezolute with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $41M | Post-IPO | – | – | |
| Jul 2019 | $20M | Post-IPO | – | – | |
| Apr 2018 | $5M | Post-IPO | – | – | |
| Feb 2018 | $3.36M | Post-IPO | – | – | – |
| Jan 2018 | $137,868 | Post-IPO | – | – | |
| Jul 2017 | $13M | Post-IPO | – | – | – |
| May 2017 | $6.73M | Post-IPO | – | – | – |
| Jan 2017 | $3.36M | Post-IPO | – | – | – |
| Nov 2016 | $10.34M | Post-IPO | – | – | – |
| Jul 2016 | $5.36M | Post-IPO | – | – | – |
7 investors in total: 7 institutional.
Investors in Rezolute
Rezolute has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Handok and Genexine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States | ||
Investment firm managing opportunistic strategies in equity and credit markets. | 2012 | camcapital.com | New York, United States | |
| federatedinvestors.com | ||||
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Pharmaceuticals, medical devices, and healthcare products are developed and marketed. | 1954 | handok.co.kr | Seoul, South Korea | |
Immunotherapeutics for orphan diseases, cancers, and autoimmune disorders are developed. | 2002 | genexine.com | Seongnam-si, South Korea |
Investor details for Rezolute
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rezolute
44 people are tracked at Rezolute (26 in leadership, 10 in board & advisors, 8 in team); the tracked headcount is 59.
| Name | Role | Group |
|---|---|---|
Nevan Charles Elam | Co-Founder & CEO | Leadership |
Hoyoung Huh | Co-Founder | Leadership |
Christen Baglaneas | Senior Director, Corporate Operations | Leadership |
Ashley Lasher | Associate Director Of Clinical Supply Chain | Leadership |
Carrie McKim | Director, Corporate Communications And Investor Relations | Leadership |
Marina Vasvary | Associate Director, Principal Scientist | Leadership |
Susan Stewart, JD, LL.M | Chief Regulatory Officer | Leadership |
Russell Santiago | Senior Director, Accounting | Leadership |
Jeffrey Breit, Ph.D. | Vice President, Drug Discovery and Pharmaceutical Sciences | Leadership |
Lucy Pan | Executive Director, Head Of Manufacturing Science And Technology | Leadership |
Robyn Sweinhart | VP & Head, Quality | Leadership |
Amanda Bell | Director Quality Compliance | Leadership |
Erin O’Boyle | VP, Clinical Operations | Leadership |
Loredie Lugos | Director of Clinical Operations | Leadership |
Sunil Karnawat | Chief Commercial Officer (cco) | Leadership |
Davelyn Eaves | Director & Head, Scientific & Patient Affairs | Leadership |
Michael R. Deperro | SVP & Head, Technical Operations | Leadership |
Raj Agrawal | VP & Head, Ophthalmological Clinical Development | Leadership |
Maya Malik | Director Of Project Management | Leadership |
Brian Roberts | SVP & Head, Clinical Development | Leadership |
24 more people are available in the full profile.
Complete people profiles for Rezolute
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rezolute
Rezolute is a publicly listed company on the NASDAQ with ticker symbol RZLT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Oct 2021
- Listed onNASDAQ: RZLT
- Listed entityRezolute, Inc.
- Exchange sectorHealth technology
- ISINUS76200L3096
- Share price$4.61 (-5.34% on the day) · 2026-10-13
- Market capitalisation$445.9M
- EPS (diluted, trailing year)$-0.75
- Volume (last session)1,507,764
Financials of Rezolute
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | -$77.6M | -$82.9M | |
| 2025 | -$74.4M | -$79.9M | |
| 2024 | -$68.5M | -$70.4M | |
| 2023 | -$51.8M | -$55.6M | |
| 2022 | -$41.1M | -$41.6M |
Detailed financial statements for Rezolute
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Rezolute
4 dated milestones of Rezolute across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Rezolute is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Post-IPO, of $41.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Rezolute
Rezolute has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Rezolute
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rezolute
The website of Rezolute (rezolutebio.com) receives about 10.5K visits a month.
- Monthly visits10.5K
▼ 10.7% vs previous month
Top companies in Diabetes
3 companies that operate in the same segment as Rezolute (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rezolute
Complete news archive for Rezolute
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rezolute
Rezolute was founded in 2012.
Rezolute is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Nevan Charles Elam is the CEO of Rezolute, as recorded in our data. They have also founded this company.
Rezolute has 59 employees.
Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI), has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) hereditary angioedema (HAE). In Dec 2017, the company had entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.
Rezolute offers Ersodetug.
Yes, Rezolute is publicly traded on NASDAQ under the ticker symbol RZLT.
Rezolute has 7 investors. Key investors include Citadel, Handok, Genexine, CAM Capital, and Federated Hermes.
Rezolute operates through Rezolute, Inc..